FDA tightens Duchenne gene therapy after deaths of two teens

The U.S. Food and Drug Administration is tightening restrictions on a gene therapy used to treat Duchenne muscular dystrophy ...
Ophthalmology Times

Coave Therapeutics reveals lead gene therapy program, CoTx-10

Coave Therapeutics has announced its lead gene therapy program, CoTx-10, for the treatment of retinal vascular diseases, such ...
Fred Hutchinson Cancer Center

Scientists see foam as starting point of a path to bedside gene therapy

Fred Hutch bioengineer Dr. Matthias Stephan is working to develop a special foam that could help make gene therapy for blood ...

🌱 Patch AM: New gene therapy center opens at Cincinnati Children's Hospital

The article 🌱 Patch AM: New gene therapy center opens at Cincinnati Children's Hospital appeared first on Cincinnati Patch.
Health and Me on MSN

Duchenne Gene Therapy: Why The FDA Has Tightened Rules Following Two Teen Deaths

The FDA has added a boxed warning to Sarepta’s Duchenne gene therapy Elevidys after two teens died from liver failure and has ...

Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth

Krystal Biotech drives Vyjuvek growth, premium margins, global expansion, a $1B goal, and pipeline data ahead with a $219.50 ...
BioSpace

FDA Imposes Boxed Warning, Narrows Patient Pool for Sarepta’s Duchenne Gene Therapy Elevidys

Sarepta must also run a post-marketing study for Elevidys to better assess the risk of serious liver injury in patients dosed ...
BioWorld

Coave nominates lead gene therapy for retinal vascular diseases

Coave Therapeutics SA has nominated a lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...

FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths

Sarepta Therapeutics’ Elevidys will carry the FDA’s strongest warning label about the risks of liver damage and liver failure ...
Becker's Hospital Review

After patient deaths, FDA to trim gene therapy’s approval

After patient deaths FDA adds boxed warning and limits Elevidys use to ambulatory Duchenne muscular dystrophy patients.
BioWorld

Johns Hopkins reports work on gene therapy for ADPKD

Developing new gene therapies for autosomal dominant polycystic kidney disease (ADPKD) is still a challenge to date. A group of researchers from the Johns Hopkins Medicine in Baltimore has presented ...